Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease

Inclusion Criteria: * 1\) Subjects who are at least 20 y of age at the time of informed consent (male or female) * 2\) Subjects with coronary heart disease longer than 3 months. * 3\) Subjects being treated with HMGCoA reductase inhibitors(Statins) * 4\) Subjects with an max IMT equal to or greater than 1.2 mm * 5\) Subjects with an LDL-Cholesterol less than 200mg/dl * 6\) Subjects whose voluntary written informed consent is obtained for participation in this study Exclusion Criteria: * 1\) Subjects who took probucol within 6 months before participation of the study * 2\) Subjects who took cilostazol within 3 months before participation of the study * 3\) Subjects with a history of hypersensitivity to probucol or cilostazol * 4\) Subjects with homozygous familial hyperlipidemia\* * 5\) Subjects with a triglyceride ( TG) level greater than 400mg/dL at screening * 6\) Subjects with uncontrolled diabetes : HbA1c level greater than 9% * 7\) Subjects with New York Heart Association (NYHA) classification: Class Ⅲ and Ⅳ * 8\) Subjects with a QTc interval greater than 450msec(male) 470msec(female) * 9\) Subjects with serious ventricular arrythmias (frequent episodes of multifocal ventricular extrasystole) * 10\) Subjects with atrial fibrillation (including paroxysmal AF) * 11\) Subjects with unstable angina * 12\) Subjects with liver and kidney functions that satisfy the following criteria - AST or ALT \>100 IU/L, serum creatinine \>1.5 mg/dL * 13\) Subjects who are participating in another clinical trial * 14\) Subjects with pregnant or possibly pregnant without appropriate contraception control. Appropriate contraception control means that Oral contraception for greater than 4 weeks, surgical contraception including loop insertion, condom use etc. Women who has no possibility of pregnancy because of surgery or menopause should not be regarded the subject with possibly pregnant * 15\) Subjects with clinically significant disorders of blood coagulation * 16\) Subjects who are not considered by the physicians to be appropriate to participate in this trial for any other reason